World Lung – Toxicity scuppers Amgen’s first-line lung hopes

Moving Kras inhibitors into first-line non-small cell lung cancer will depend on getting a result with a checkpoint inhibitor combination. Following promising but early data from Mirati here, Amgen has recently been playing down the prospects of a Lumakras-PD-(L)1 tie-up – and results presented yesterday at the World Lung meeting explain why.